XML 45 R39.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue Recognition and Collaboration Arrangements        
Total net royalty revenue $ 107,800 $ 89,508 $ 296,715 $ 266,905
Royalty Revenue        
Revenue Recognition and Collaboration Arrangements        
Total net royalty revenue 59,896 57,056 181,583 179,213
GSK | Royalty Revenue        
Revenue Recognition and Collaboration Arrangements        
Total royalties 63,352 60,512 191,951 189,581
Less: amortization of capitalized fees paid (3,456) (3,456) (10,368) (10,368)
Total net royalty revenue 59,896 57,056 181,583 179,213
GSK | ANORO        
Revenue Recognition and Collaboration Arrangements        
Total royalties 11,844 12,313 34,816 35,264
GSK | RELVAR/BREO        
Revenue Recognition and Collaboration Arrangements        
Total royalties $ 51,508 $ 48,199 $ 157,135 $ 154,317